Eaton Vance Management Fate Therapeutics Inc Transaction History

Eaton Vance Management

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $16,170 - $32,852	-545 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $16,121 - $26,038	272 Added 99.63%	545 $32,000
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $807 - $1,110	-12 Reduced 4.21%	273 $24,000
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $20,565 - $33,459	285 New	285 $23,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

Stay updated on Eaton Vance Management with notifications on news.